Drug Trial Radar · NCT07926893
Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
14
Planned (sponsor's estimate)
Start
May 16, 2027
Primary completion
May 16, 2028
Study completion May 16, 2028
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety, side effects and best dose of lenalidomide in combination with cosibelimab for the treatment of patients with mycosis fungoides or Sézary syndrome that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory).Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Immunotherapy with monoclonal antibodies, such as cosibelimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide in combination with cosibelimab may be safe and tolerable in treating patients with relapsed or refractory mycosis fungoides or Sézary syndrome.
Conditions
- Recurrent Mycosis Fungoides
- Recurrent Sezary Syndrome
- Recurrent Transformed Mycosis Fungoides
- Refractory Mycosis Fungoides
- Refractory Sezary Syndrome
- Refractory Transformed Mycosis Fungoides
- Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8
- Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT scan
CosibelimabDrug
Given IV
LenalidomideDrug
Given PO
Positron Emission TomographyProcedure
Undergo PET scan
Questionnaire AdministrationOther
Ancillary studies
Skin BiopsyProcedure
Undergo skin biopsy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLT)Time frame: From baseline, up to completion of cycle 3 (cycle length = 21 days)
- Incidence of adverse eventsTime frame: Up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.